Display options
Cite
Sevim KZ, Silistreli O, Gorgu M, et al. Short-term vasculoprotective effects of imatinib mesylate on intimal hyperplasia of arterial anastomosis: An experimental study using a rabbit model. Can J Plast Surg. 2012;20(4):223-8doi: 10.1177/229255031202000414.
Sevim, K. Z., Silistreli, O., Gorgu, M., Sevim, O., & Ergur, B. (2012). Short-term vasculoprotective effects of imatinib mesylate on intimal hyperplasia of arterial anastomosis: An experimental study using a rabbit model. The Canadian journal of plastic surgery = Journal canadien de chirurgie plastique, 20(4), 223-8. https://doi.org/10.1177/229255031202000414
Sevim, Kamuran Zeynep, et al. "Short-term vasculoprotective effects of imatinib mesylate on intimal hyperplasia of arterial anastomosis: An experimental study using a rabbit model." The Canadian journal of plastic surgery = Journal canadien de chirurgie plastique vol. 20,4 (2012): 223-8. doi: https://doi.org/10.1177/229255031202000414
Sevim KZ, Silistreli O, Gorgu M, Sevim O, Ergur B. Short-term vasculoprotective effects of imatinib mesylate on intimal hyperplasia of arterial anastomosis: An experimental study using a rabbit model. Can J Plast Surg. 2012;20(4):223-8. doi: 10.1177/229255031202000414. PMID: 24294014; PMCID: PMC3513249.
Copy Download .nbib Format: NLM
Share it on

Can J Plast Surg. 2012;20(4):223-8. doi: 10.1177/229255031202000414.

Short-term vasculoprotective effects of imatinib mesylate on intimal hyperplasia of arterial anastomosis: An experimental study using a rabbit model.

The Canadian journal of plastic surgery = Journal canadien de chirurgie plastique

Kamuran Zeynep Sevim, Ozlem Silistreli, Metin Gorgu, Osman Sevim, Bekir Ergur

Affiliations

  1. Sisli Etfal Research and Training Hospital Department of Plastic Surgery, Istanbul;

PMID: 24294014 PMCID: PMC3513249 DOI: 10.1177/229255031202000414

Abstract

BACKGROUND: Since the beginning of the 'microvascular era', the success rates of microvascular procedures have increased to more than 90% in most series. The main reason for failure, however, is the healing of microarterial anastomosis, which is dependent on the status of endothelial cells and affects the rate of arterial thrombosis. In 80% of arterial thrombosis cases, complications are primarily observed during the first 72 h after surgery. Healing of arterial anastomosis results in intimal hyperplasia in which myofibroblasts comprise the predominant cell type. Intimal hyperplasia has been described previously as an adaptive process that occurs in response to hemodynamic stress or injuries to the vascular bed. During wound healing, fibroblasts proliferate, migrate and differentiate into myofibroblasts - a process that takes one to three days. Imatinib mesylate (ST1571-Gleevec, Novartis, Germany) is a specific platelet-derived growth factor receptor blocker that has found use as an adjunct to sirolimus in cardiovascular surgery for restenosis. However, its potential utility in preventing arterial thrombosis in microvascular surgery has not been evaluated in routine plastic surgery practice.

METHODS: Twenty-four randomly selected, male, white New Zealand rabbits were divided into six groups (A to F), and the femoral artery model was used for arterial anastomosis. Following anastomosis, groups A, B and C received phosphate-buffered saline orogastrically. In groups D, E and F, imatinib mesylate was administered via an orogastric tube twice per day at a dose of 10 mg/kg starting two days before arterial anastomosis. Following anastomosis, imatinib mesylate was administered for one, three and seven days, and the regression of intimal hyperplasia was recorded.

RESULTS: In groups administered imatinib mesylate (ie, groups D, E and F), intimal hyperplasia decreased by up to 50%, which represented a statistically significant difference. Histological analysis confirmed smooth muscle cell migration from the tunica intima to media on days 3 and 7 in groups E and F.

CONCLUSION: The present study revealed that imatinib mesylate, which was initiated as a prophylactic, systemic pretreatment and continued for seven days, gradually decreased intimal hyperplasia at the anastomosis site.

Keywords: Imatinib mesylate; Intimal hyperplasia; Thrombosis

References

  1. Zhonghua Zhong Liu Za Zhi. 2011 Jun;33(6):470-2 - PubMed
  2. Perfusion. 2012 Nov;27(6):520-8 - PubMed
  3. Nat Med. 2002 Apr;8(4):403-9 - PubMed
  4. Head Neck. 1999 Jul;21(4):355-62 - PubMed
  5. Lab Invest. 1983 Aug;49(2):208-15 - PubMed
  6. Vascul Pharmacol. 2009 Jul;51(1):50-6 - PubMed
  7. N Engl J Med. 2002 Feb 28;346(9):683-93 - PubMed
  8. Am J Clin Pathol. 2003 Jun;119(6):833-41 - PubMed
  9. Eur J Vasc Surg. 1992 Jul;6(4):343-5 - PubMed
  10. Circulation. 1992 Dec;86(6 Suppl):III47-52 - PubMed
  11. Plast Reconstr Surg. 1990 Jul;86(1):110-7 - PubMed
  12. Circ Res. 2006 Sep 15;99(6):617-25 - PubMed
  13. Anadolu Kardiyol Derg. 2011 Mar;11(2):93-100 - PubMed
  14. Circ Res. 1993 Jul;73(1):193-204 - PubMed
  15. Microsurgery. 1998;18(7):391-6 - PubMed
  16. Plast Reconstr Surg. 1994 Mar;93(3):472-8; discussion 479-80 - PubMed
  17. Blood. 1997 Dec 15;90(12):4947-52 - PubMed
  18. Cardiovasc Drugs Ther. 1999 Apr;13(2):159-68 - PubMed
  19. Plast Reconstr Surg. 1977 Dec;60(6):868-75 - PubMed
  20. Plast Reconstr Surg. 1996 Dec;98(7):1230-3 - PubMed
  21. Tohoku J Exp Med. 2008 Aug;215(4):299-306 - PubMed
  22. Scand J Plast Reconstr Surg. 1980;14(1):65-70 - PubMed
  23. J Reconstr Microsurg. 2000 Nov;16(8):589-92 - PubMed
  24. Circ Res. 1985 Jan;56(1):139-45 - PubMed
  25. Am J Physiol. 1995 Nov;269(5 Pt 2):H1641-7 - PubMed
  26. Circulation. 2004 Mar 9;109(9):1140-6 - PubMed
  27. Cell. 1986 Jul 18;46(2):155-69 - PubMed
  28. J Reconstr Microsurg. 2002 Oct;18(7):579-84 - PubMed
  29. J Vasc Res. 2009;46(3):240-52 - PubMed
  30. Scand J Plast Reconstr Surg. 1981;15(2):103-10 - PubMed
  31. J Cardiothorac Surg. 2012 Jun 20;7:57 - PubMed
  32. Circulation. 1996 Jun 15;93(12):2178-87 - PubMed
  33. J Reconstr Microsurg. 2000 May;16(4):297-301 - PubMed
  34. N Engl J Med. 2001 Apr 5;344(14):1031-7 - PubMed

Publication Types